AHCLNSEAnlon Healthcare Limited· Pharmaceuticals & BiotechnologyHighNegative
Announced Mon, 9 Feb, 2026 · 16:36 IST

CFO resigns, new CFO and Independent Director appointed, Q3 results

Cfo ResignedKmp ResignedManagement Changes View source PDFExplain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.4%Reaction day
₹12.68
prior close
₹12.87
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.0%-3.4% vs market
Pharmaceuticals peers, median of 159sector+0.4%-2.9% vs sector

On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.1
10m
-1.7
15m
-1.7
30m
-2.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.4+1.0-3.4+0.4-2.9
Next day
-3.0+0.5-3.5+0.3-3.3
2d
-3.9-0.0-3.9+0.0-3.9
3d
-4.6-1.5-3.1-1.2-3.4
4d
-4.8-2.2-2.6-1.7-3.1
5d
-3.9-1.2-2.7-1.8-2.2
1w
-7.7-2.4-5.4-2.5-5.2
15d
-14.0-8.8-5.2-6.9-7.1
1m
-1.1-8.3+7.2-5.1+4.0
2m
+2.2-3.5+5.8-3.5+5.7
3m
+12.0+6.4+5.6+2.8+9.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q3 FY26 results showing revenue of Rs 35.58 crore (down from Rs 71.36 crore YoY) and PAT of Rs 5.15 crore. CFO Hitesh Makwana resigned citing pre-occupation; Naimish Bhatt (18 yrs exp) appointed new CFO. Independent Director Shailesh Thakkar resigned citing health issues; Kishan Raja (CA, 14 yrs) appointed. IPO funds fully on track with no deviation.

Likely market impact

Multiple board changes alongside weak Q3 results. New appointments bring finance expertise. Watch transition closely.